CA
BCAX

Cliff Asness’s Bicara Therapeutics BCAX Stock Holding History

Cliff Asness’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$888K Buy
29,917
+16,731
+127% +$373K ﹤0.01% 3070
2026
Q1 		$262K Buy
+13,186
New +$227K ﹤0.01% 3474
2025
Q2 		– Sell
-19,034
Closed -$248K – 3413
2025
Q1 		$248K Buy
+19,034
New +$253K ﹤0.01% 2776

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Cliff Asness's BCAX Position: Q2 2026 in Review

Cliff Asness increased its Bicara Therapeutics (BCAX) stake by 127% in Q2 2026, buying an estimated $373K and bringing the position to 29,917 shares worth $888K. The position accounts for ﹤0.01% of the portfolio, ranked #3070.

Cliff Asness first reported a position in BCAX in Q1 2025 and has held it in 3 quarters since. 169 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Cliff Asness held 29,917 shares of Bicara Therapeutics worth $888K as of Q2 2026.
  • Cliff Asness bought 16,731 Bicara Therapeutics shares in Q2 2026, an estimated $373K.
  • Bicara Therapeutics made up ﹤0.01% of Cliff Asness's portfolio in Q2 2026, its #3070 holding.
  • Cliff Asness first reported a position in Bicara Therapeutics in Q1 2025 and has held it in 3 quarters since.
  • 169 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.